Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
CC transcript
Director departure
Inv. presentation
Appointed director

Stereotaxis, Inc. (STXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Stereotaxis Reports 2023 Second Quarter Financial Results"
05/19/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Stereotaxis Reports 2023 First Quarter Financial Results"
03/03/2023 8-K Quarterly results
Docs: "Stereotaxis Reports 2022 Full Year Financial Results"
11/10/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Stereotaxis Reports 2021 Third Quarter Financial Results"
08/27/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
07/26/2021 8-K Appointed a new director
Docs: "Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D."
05/20/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
12/18/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT is made as of this 17 th day of December, 2020, by and between Stereotaxis, Inc., a Delaware corporation , and David L. Fischel . RECITAL WHEREAS, the parties desire to enter into this Agreement setting forth the terms and conditions for the employment relationship between Employee and the Company in connection with Employee’ s continuing role as Chief Executive Officer of the Company. NOW, THEREFORE, in consideration of the promises and mutual covenants and agreements herein contained and intending to be legally bound hereby, the Company and Employee hereby agree as follows: 1. Position; Base Salary . Employee shall serve as Chief Executive Officer , and shall report to the Board of Directors of the Company . Employee shal..."
11/09/2020 8-K Quarterly results
Docs: "Stereotaxis Reports 2020 Third Quarter Financial Results"
08/06/2020 8-K Quarterly results
05/26/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Opinion of Bryan Cave Leighton Paisner LLP",
"Securities Purchase Agreement between the Company and the Investors",
"Stereotaxis Announces $15 Million Common Stock Financing"
05/05/2020 8-K Quarterly results
04/20/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/10/2020 8-K Quarterly results
11/14/2019 8-K Quarterly results
09/16/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Stereotaxis Announces CFO Transition ST. LOUIS, MO, Sept. 16, 2019 – Stereotaxis , the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, effective October 1, 2019. Martin Stammer, who has served as Chief Financial Officer since 2013, has accepted a position as the CFO of a large professional services firm headquartered in the St. Louis area and will resign from the Company, effective September 30, 2019. “I have really enjoyed my time at Stereotaxis and firmly believe in the future of the Company,” said Martin Stammer. “I have the utmost confidence in Kim and her team and look forward to seeing them achieve many additional milestones.” Kimberly Peery joined St..."
08/22/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Stereotaxis, Inc. Unaudited Actual and As Adjusted Balance Sheet as of June 30, 2019"
08/08/2019 8-K Quarterly results
08/08/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock",
"Securities Purchase Agreement by and among Stereotaxis, Inc. and the investors listed on the Schedule of Buyers attached thereto",
"Registration Rights Agreement by and among Stereotaxis, Inc. and the Buyers party thereto",
"Stereotaxis Announces $25 Million Private Placement ST. LOUIS, MO, August 8, 2019 – Stereotaxis , the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select institutional investors for a $25 million private placement. In this private placement, Stereotaxis is selling approximately 12.2 million shares of common stock and convertible preferred stock at a purchase price of $2.05 per share to select healthcare-focused and growth-oriented institutional investors. The preferred stock is a common stock equivalent but non-voting and with a blocker on conversion into common stock if the holder would exceed a specified threshold of voting security ownership. The financing was led ..."
07/01/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amendment to and Reinstatement of Third Amended and Restated Loan and Security Agreement, between Silicon Valley Bank, the Company, and Stereotaxis International, Inc"
05/21/2019 8-K Submission of Matters to a Vote of Security Holders
05/09/2019 8-K Quarterly results
Docs: "Stereotaxis Reports 2019 First Quarter Financial & Operational Results ST. LOUIS, MO, May 9, 2019 – Stereotaxis , the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2019. In separate press releases issued concurrently with this release, Stereotaxis showcased for the first time a next-generation robotic system, a novel x-ray imaging system, and a development program for a proprietary robotically-navigated magnetic ablation catheter. “The start of 2019 is highlighted by significant innovation accomplishments across all key aspects of our technology,” said David Fischel, Chairman and CEO. “These innovations will positively impact patient care, the physician experience, and the br..."
03/12/2019 8-K Quarterly results
Docs: "Stereotaxis Reports 2018 Full Year Financial Results ● Record high annual recurring revenue of $27.8 million; 3% annual growth ● Positive annual net income for the first time in Company history despite significantly increased R&D investments ● Innovation initiatives to be showcased in May at Heart Rhythm Society meeting ● Strong financial position to reach profitability without the need for additional financings ● Conference call today at 10:00 a.m. Eastern Time ST. LOUIS, MO, March 12, 2019 – Stereotaxis, Inc. , the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an extremely active year at Stereotaxis with progre..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy